Breaking Medical Technology News: Aethlon
Medical (NASDAQ: $AEMD) to Release Fiscal Third Quarter Financial Results and
Host Conference Call on February 12, 2025
SAN
DIEGO, CA - February 5, 2025 (Investorideas.com Newswire) Aethlon Medical, Inc.
(Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat
cancer and life threatening infectious diseases, today announced that it will
issue financial results for its fiscal third quarter ended December 31, 2024,
at 4:15 p.m. ET on Wednesday, February 12, 2025.
Management will host a conference
call on Wednesday, February 12, 2024, at 4:30 p.m. ET to review financial
results and recent corporate developments. Following management's formal
remarks, there will be a question and answer session.
Paid News Dissemination of behalf of AEMD.
Read
this news, featuring AEMD in full at https://www.investorideas.com/news/2025/02051AEMD-Fiscal-Q3-Financial-Results-Conference-Call.asp
Interested parties can register for
the conference call by navigating to https://dpregister.com/sreg/10196811/fe7c419c9d.
Please note that registered participants will receive their dial-in number upon
registration.
Interested parties without internet
access or unable to pre-register may dial in by calling:
PARTICIPANT DIAL IN (TOLL FREE):
1-844-836-8741
PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442
All callers should ask for the
Aethlon Medical, Inc. conference call.
A replay of the call will be
available approximately one hour after the end of the call through March 12,
2025. The replay can be accessed via Aethlon Medical's website or by dialing
1-877-344-7529 (domestic) or 1-412-317-0088 (international) or Canada toll free
at 1-855-669-9658. The replay conference ID number is 7828175.
About Aethlon and the Hemopurifier®
Aethlon Medical is a medical therapeutic
company focused on developing the Hemopurifier, a clinical stage
immunotherapeutic device which is designed to combat cancer and
life-threatening viral infections and for use in organ transplantation. In
human studies, the Hemopurifier has demonstrated the removal of
life-threatening viruses and in pre-clinical studies, the Hemopurifier has
demonstrated the removal of harmful exosomes from biological fluids, utilizing
its proprietary lectin-based technology. This action has potential applications
in cancer, where exosomes may promote immune suppression and metastasis, and in
life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug
Administration (FDA) designated Breakthrough Device indicated for the treatment
of individuals with advanced or metastatic cancer who are either unresponsive
to or intolerant of standard of care therapy, and with cancer types in which
exosomes have been shown to participate in the development or severity of the
disease. The Hemopurifier also holds an FDA Breakthrough Device designation and
an open Investigational Device Exemption (IDE) application related to the
treatment of life-threatening viruses that are not addressed with approved
therapies.
Additional information can be found
at www.AethlonMedical.com
Forward Looking Statements
This press release contains
forward-looking statements within the meaning of Section 27A of the Securities
Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve
risks and uncertainties. Statements containing words such as "may,"
"believe," "anticipate," "expect,"
"intend," "plan," "project," "will,"
"projections," "estimate," "potentially" or
similar expressions constitute forward-looking statements. Such forward-looking
statements are subject to significant risks and uncertainties and actual
results may differ materially from the results anticipated in the
forward-looking statements. These forward-looking statements are based upon
Aethlon's current expectations and involve assumptions that may never
materialize or may prove to be incorrect. All forward-looking statements
contained in this press release speak only as of the date on which they were
made. Except as may be required by law, the Company does not intend, nor does
it undertake any duty, to update this information to reflect future events or
circumstances.
Company Contact:
Jim Frakes
Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
SOURCE Aethlon Medical, Inc.
Aethlon
Medical Inc. (Nasdaq:AEMD) is a featured biotech stock on Investorideas.com
More info on AEMD at Investorideas.com Visit:
https://www.investorideas.com/CO/AEMD/
Get News
Alerts on Aethlon Medical
Disclaimer/Disclosure: Athelon
Medical, Inc. (AEMD) is a paid featured medical tech stock on
Investor ideas More disclosure:Investorideas.com is a digital publisher of third party sourced news,
articles and equity research as well as creates original content, including
video, interviews and articles. Original content created by investorideas is
protected by copyright laws other than syndication rights. Our site does not
make recommendations for purchases or sale of stocks, services or products.
Nothing on our sites should be construed as an offer or solicitation to buy or
sell products or securities. All investing involves risk and possible losses.
This site is currently compensated for news publication and distribution,
social media and marketing, content creation and more. More disclosure: Contact management and IR of each company directly regarding
specific questions.
Biotech Industry Stocks- investing ideas
in biotechnology stocks, medical technology and life sciences
Get more biotech and medical tech news,
articles, podcasts and stock directories
